Nicholas Hamm

With worsening storms and other natural disasters, it’s more important than ever for healthcare executives to pay attention to emergency power supplies.

A new NIH report on cancer in people aged 20 to 49 shows that while rates are declining, women and minorities still face significant rates.

The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.

A new report shows that the new open enrollment rules are leading to increased Medicare Advantage uptake.

New definition of burnout to be included in forthcoming ICD-11.

In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.

A new study shows that members who enroll in Medicare Advantage plans may have lower spending.

Drug costs are a hot political topic, but just how much do they disrupt healthcare?

From tips for new healthcare leaders to growing initiatives, Andrea Walsh shows why people are the most important part of every part of healthcare.

The falsehoods being spread about biosimilars that don’t match up with reality.

How technologies are helping health systems think about-and mobilize on-social determinants of health.

Technical skills aren’t enough to effectively manage an organization-you need other skills they don’t teach in school.

Gene therapy offers great hope for patients, but comes with a bevy of challenges for patients and payers alike.

The tools and processes one of the largest not-for-profit Medicare Advantage plans uses to help seniors.

Jim Barlow of Geneos Therapeutics explains the role of value networks and strategies to increase cell therapy access.

Are you getting the most out of your smartphone? From more knowledge to great efficiencies, these apps can get you more hours in a day.

IO therapies hold great promise, but often come with high price tags. How do payers feel about these medications?

A look at what could be some of the biggest and most important drugs of the year.

These 10 states have the worst cancer rates in the entire country.

The places where cancer mortality rates are the highest.

Biosimilars hold great cost savings promises for payers and patients alike-but only if prescribers and patients are willing to make the switch.

Good leaders don’t just rely on one managerial style-they get the best out of every team member by meeting their needs.

Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.

Specialty pharmaceuticals make up a huge part of the current drug market, and their impact is only going to grow over the next few years.

How can payers cope with new, ultra-expensive therapies?

Decades of research has led to a flurry of new warnings.